Home > Chemocentryx Salary

Chemocentryx Salary

  • 77
  • 90
  • 61
Chemocentryx average salary is $100,000, median salary is $100,000 with a salary range from $80,000 to $120,000.
Chemocentryx salaries are collected from government agencies and companies. Each salary is associated with a real job position. Chemocentryx salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 2 Chemocentryx Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Electrical Engineer 80,000-80,000 Longview, WA, 98632 2012 Chemocentryx Electrical Engineer Salaries (1)
Chemocentryx Longview, WA Salaries
Maintenance Engineering Manager 120,000-120,000 Longview, WA, 98632 2012 Chemocentryx Maintenance Engineering Manager Salaries (1)
Chemocentryx Longview, WA Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Chemocentryx salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Chemocentryx Jobs
See more Chemocentryx Jobs»
Search All Jobs

JobsOpenHiring – Find open jobs faster
Chemocentryx... Information
  • ChemoCentryx, Inc
  • Industry: BioTech/Drugs
  • City: Mountain View, CA
  • ChemoCentryx, Inc. discovers, develops and commercializes novel small molecule medicines for autoimmune diseases, inflammatory disorders, cancer and infectious disease. Traficet-EN(TM), the company's orally active drug for inflammatory bowel disease, will enter clinical trials in 2003. Other products include an orally active development candidate for rheumatoid arthritis and multiple sclerosis, and emerging drug candidates for cancer and cardiopulmonary inflammation. Another drug, T487, resulted from a ChemoCentryx discovery program and is expected to enter Phase II clinical trials for psoriasis in 2003 with partner Tularik Inc. Leveraging its leadership in chemokine-based drug discovery, ChemoCentryx focuses on new classes of orally active small